216 related articles for article (PubMed ID: 20071306)
21. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
23. Intraoperative presacral electron boost following preoperative chemoradiation in T3-4Nx rectal cancer: initial local effects and clinical outcome analysis.
Calvo FA; Gómez-Espí M; Díaz-González JA; Alvarado A; Cantalapiedra R; Marcos P; Matute R; Martínez NE; Lozano MA; Herranz R
Radiother Oncol; 2002 Feb; 62(2):201-6. PubMed ID: 11937247
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
[TBL] [Abstract][Full Text] [Related]
25. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Braendengen M; Tveit KM; Berglund A; Birkemeyer E; Frykholm G; Påhlman L; Wiig JN; Byström P; Bujko K; Glimelius B
J Clin Oncol; 2008 Aug; 26(22):3687-94. PubMed ID: 18669453
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
28. [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Liersch T; Langer C; Jakob C; Müller D; Ghadimi BM; Siemer A; Markus PM; Füzesi L; Becker H
Chirurg; 2003 Mar; 74(3):224-34. PubMed ID: 12647079
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
30. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?
Hughes R; Harrison M; Glynne-Jones R
Acta Oncol; 2010 Apr; 49(3):378-81. PubMed ID: 20151936
[TBL] [Abstract][Full Text] [Related]
31. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.
Gambacorta MA; Valentini V; Coco C; Morganti AG; Smaniotto D; Miccichè F; Mantini G; Barbaro B; Garcia-Vargas JE; Magistrelli P; Picciocchi A; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):139-48. PubMed ID: 15337549
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
33. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
34. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Cafiero F; Gipponi M; Lionetto R;
J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
36. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia.
Tuta M; Boc N; Brecelj E; Omejc M; Anderluh F; Ermenc AS; Peressutti AJ; Oblak I; Krebs B; Velenik V
Radiol Oncol; 2019 Oct; 53(4):465-472. PubMed ID: 31652124
[TBL] [Abstract][Full Text] [Related]
37. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
Gérard JP; Chapet O; Nemoz C; Romestaing P; Mornex F; Coquard R; Barbet N; Atlan D; Adeleine P; Freyer G
J Clin Oncol; 2003 Mar; 21(6):1119-24. PubMed ID: 12637479
[TBL] [Abstract][Full Text] [Related]
38. [Indications for neoadjuvant therapy in rectal carcinoma].
Zimmermann F; Molls M
Chirurg; 2003 Oct; 74(10):887-96. PubMed ID: 14605730
[TBL] [Abstract][Full Text] [Related]
39. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
Vecchio FM; Valentini V; Minsky BD; Padula GD; Venkatraman ES; Balducci M; Miccichè F; Ricci R; Morganti AG; Gambacorta MA; Maurizi F; Coco C
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):752-60. PubMed ID: 15936556
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and histopathological results after the neo-adjuvant treatment of advanced rectal tumors].
Varga L; Baradnay G; Hohn J; Simonka Z; Hideghéthy K; Maráz A; Nikolényi A; Veréb B; Tiszlavicz L; Németh I; Mán E; Lázár G
Magy Onkol; 2010 Jun; 54(2):129-35. PubMed ID: 20576589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
